Stay updated with breaking news from Benefit Managers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Juliana Reed, MS, believes that there should be legislative incentives and preferred status for lower cost biosimilars in all government programs, with robust competition and accountability for PBMs not to limit access.
The Biosimilars Forum is concerned with the limited access to lower-cost biosimilars, specifically regarding the 8 adalimumab biosimilars set to launch in July, due to pharmacy benefits managers controlling access to 80% of the US market.
Treasury Department and IRS Release Preliminary Guidance on Semiconductor Tax Credit. On March 23, the Treasury Department and IRS published proposed regulations for implementing the...
Senate voted to end COVID 19 national emergency other action related to healthcare was at committee level. FY 2024 budget hearings continued and other health related hearings included House Energy and Commerce Committee hearing focused on transparency and competition
Dear Colleague, The term "mom and pop" business had always bothered me. I thought it sounded a bit condescending and dismissive when I would hear representatives from big businesses talk about it, almost like they were giving small business owners a little pat on the head. But Wednesday was "Mom and Pop Business Owner's Day," and my attitude about the phrase evolved during a week in D.C. when independent pharmacies were in the spotlight.